Genomic Health

Genomic Health, Almac collaborate on test to predict chemotherapy benefits

Wednesday, November 27, 2013

Genomic Health, a provider of genomic-based diagnostic tests, will exclusively license Almac Group’s technology and intellectual property to further develop, validate and subsequently commercialize a multi-gene test to predict benefit from DNA damage-based chemotherapy drugs, such as the commonly used anthracycline-based regimens, in breast cancer.  Such a test would be particularly useful for high-risk breast cancer patients who are eligible for chemotherapy based on their Oncotype DX score. 

[Read More]

Genomic launches breast cancer trial

Wednesday, April 27, 2011

Genomic Health has launched RxPONDER S1007, a breast cancer clinical trial being led by SWOG, one of the National Cancer Institute’s (NCI) cancer cooperative groups.  The trial is designed to determine the effect of chemotherapy in breast cancer patients with one to three positive nodes who have a Recurrence Score (RS) result equal to, or less than, 25 as determined by the Oncotype DX breast cancer test.

[Read More]